What is the 13F Pro Quality Score for DNTH?

13F Pro ranks Dianthus Therapeutics, Inc. /DE/ (DNTH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DNTH's current score at https://13fpro.ai/company/DNTH (free sign-up required for the full ranking).

Which hedge funds own the most DNTH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DNTH include FMR, BlackRock,, T. Rowe Price Investment Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/DNTH as soon as new 13F filings post.

Where does 13F Pro source DNTH data?

All Dianthus Therapeutics, Inc. /DE/ fundamentals and ownership data come directly from SEC EDGAR. Dianthus Therapeutics, Inc. /DE/ files with the SEC under CIK 1690585. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DNTH in?

Dianthus Therapeutics, Inc. /DE/ (DNTH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DNTH research updated on 13F Pro?

DNTH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Dianthus Therapeutics, Inc. /DE/(DNTH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1690585 DNTH stock profile & AI dashboard →

13F Pro Quality Score

22.6/100

Rank #2,746 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

84.5/100

Profitability

1.3/100

Balance Sheet

9.3/100

Earnings Quality

21.1/100

Free Cash Flow

1.2/100

Institutional Flow

35.4/100

Revenue Scale

1.6/100

Dilution Risk

0.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why DNTH Scores 23/100

exact factor attribution · 2026-09-11

DNTH's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.9 pts

85th pct

Institutional flow

-0.7 pts

35th pct

Earnings growth

-2.3 pts

4th pct

Shareholder dilution

-2.5 pts

1th pct

Earnings quality

-2.9 pts

21th pct

Capital efficiency

-4.1 pts

9th pct

Scale

-7.3 pts

2th pct

Profitability

-7.3 pts

1th pct

Free cash flow

-7.3 pts

1th pct

Latest change (2026-08-06): 27 → 7 · ↓ Profit margin 30→1; ↓ Revenue growth 30→2

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in DNTH

Events flagged as statistical outliers against DNTH's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-06
DNTH quality score dropped 20 points (27→7) on a new filing
View source filing →

DNTH Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Dianthus Therapeutics, Inc. /DE/ (DNTH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DNTH at 22.6/100 on a 32-signal composite quality model, placing it at rank #2,746 of 2,961 stocks — the bottom half of the AI-ranked universe. DNTH scores in the top quartile across revenue growth (84.5). Areas of concern include free cash flow (1.2) and profitability (1.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.7/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of DNTH by reported 13-F value include FMR, BlackRock, T. Rowe Price Investment Management, based on the most recent SEC filings. DNTH trades on the Nasdaq exchange and files with the SEC under CIK 1690585. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dianthus Therapeutics, Inc. /DE/ directly from SEC EDGAR. Dianthus Therapeutics, Inc. /DE/'s 13F Pro composite quality score has ranged between 6 and 25 since 2024, currently 22.6 — a stable long-term trajectory across 55 quarterly and live scoring snapshots.

✦

Fun facts about Dianthus Therapeutics, Inc. /DE/

Quirks, history, and lore behind DNTH — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in New York · focused on serious inflammatory and autoimmune diseases.
2
The Numbers
Like most clinical-stage biotechs, it has no product revenue yet — it runs on cash reserves and has a relatively small headcount, typical of a pre-commercial biotech.
3
The History
The company was spun out of Verseon — wait, no — it was formed out of assets and talent from Anokion and relaunched as an independent public company in the early 2020s.
4
The Secret
Its lead therapeutic approach zeroes in on BAFF and APRIL — two proteins that keep disease-causing B cells alive longer than they should be.
5
The Lore
Its lead drug candidate targets IgA nephropathy — a kidney disease caused by rogue antibodies — using a bispecific antibody designed to cut off the fuel supply to misbehaving immune cells.
6
The Giveaway
Named after a genus of flowering carnation plants, this biotech's ticker is DNTH and its lead asset DNTH103 is gunning to make a name in complement-driven kidney disease.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-50.2M

ROIC

Q2 2026

-21.0%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-67.3% YoY

$2.0MFY 2025

FY22 $6.4MFY23 $2.8MFY24 $6.2MFY25 $2.0M

Net Income

-91.1% YoY

$-162.3MFY 2025

FY22 $-28.5MFY23 $-43.6MFY24 $-85.0MFY25 $-162.3M

Operating Income

-74.7% YoY

$-177.9MFY 2025

FY22 $-29.7MFY23 $-48.2MFY24 $-101.9MFY25 $-177.9M

EPS (Diluted)

-64.7% YoY

$-4.20FY 2025

FY22 $-32.57FY23 $-8.45FY24 $-2.55FY25 $-4.20

Total Assets

+42.0% YoY

$530.9MFY 2025

FY22 $83.1MFY23 $179.4MFY24 $374.0MFY25 $530.9M

Op. Cash Flow

-65.1% YoY

$-129.1MFY 2025

FY22 $-29.1MFY23 $-36.9MFY24 $-78.2MFY25 $-129.1M

Free Cash Flow

—FY 2025

FY22 $-29.4MFY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.0M -67.3%	$6.2M +120.6%	$2.8M -56.0%	$6.4M +334.8%	$1.5M	—
Net Income	$-162.3M -91.1%	$-85.0M -95.1%	$-43.6M -53.0%	$-28.5M +60.0%	$-71.1M +5.1%	$-74.9M
Operating Income	$-177.9M -74.7%	$-101.9M -111.5%	$-48.2M -62.2%	$-29.7M +60.2%	$-74.7M +5.1%	$-78.7M
EPS (Diluted)	$-4.20 -64.7%	$-2.55 +69.8%	$-8.45 +74.1%	$-32.57 -2424.8%	$-1.29 +24.6%	$-1.71
Total Assets	$530.9M +42.0%	$374.0M +108.5%	$179.4M +115.9%	$83.1M -56.2%	$189.9M +17.5%	$161.6M
Operating Cash Flow	$-129.1M -65.1%	$-78.2M -112.1%	$-36.9M -26.8%	$-29.1M +51.2%	$-59.5M +7.0%	$-64.0M
Free Cash Flow	—	—	—	$-29.4M +51.7%	$-60.8M +5.6%	$-64.4M

Get alerted when DNTH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Dianthus Therapeutics, Inc. /DE/ including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DNTH

FMR LLC
$799.3M8,199,893 sh
BlackRock, Inc.
$402.0M4,123,822 sh
T. Rowe Price Investment Management, Inc.
$379.0M3,888,456 sh
WELLINGTON MANAGEMENT GROUP LLP
$314.8M3,229,882 sh
Fairmount Funds Management LLC
$247.3M2,537,191 sh
PRICE T ROWE ASSOCIATES INC /MD/
$245.2M2,514,946 sh
STATE STREET CORP
$229.8M2,357,440 sh
VANGUARD CAPITAL MANAGEMENT LLC
$210.5M2,159,568 sh
Avidity Partners Management LP
$205.1M2,104,184 sh
Octagon Capital Advisors LP
$179.5M1,841,667 sh

Fund	Value	Shares
FMR LLC	$799.3M	8,199,893
BlackRock, Inc.	$402.0M	4,123,822
T. Rowe Price Investment Management, Inc.	$379.0M	3,888,456
WELLINGTON MANAGEMENT GROUP LLP	$314.8M	3,229,882
Fairmount Funds Management LLC	$247.3M	2,537,191
PRICE T ROWE ASSOCIATES INC /MD/	$245.2M	2,514,946
STATE STREET CORP	$229.8M	2,357,440
VANGUARD CAPITAL MANAGEMENT LLC	$210.5M	2,159,568
Avidity Partners Management LP	$205.1M	2,104,184
Octagon Capital Advisors LP	$179.5M	1,841,667

Companies Similar to DNTH

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

AVTX

Avalo Therapeutics, Inc.

AI score

Very similar · 16 shared holders

TCG Crossover Management, LLC Affinity Asset Advisors, LLC BRAIDWELL LP

NAMS

NewAmsterdam Pharma Co N.V.

AI score

Very similar · 21 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)JENNISON ASSOCIATES LLC Polar Capital Holdings Plc

OCUL

OCULAR THERAPEUTIX, INC

AI score

Very similar · 17 shared holders

VR Adviser, LLC Logos Global Management LP Octagon Capital Advisors LP

IDYA

IDEAYA Biosciences, Inc.

AI score

Very similar · 24 shared holders

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)BAKER BROS. ADVISORS LP Logos Global Management LP

CBIO

CRESCENT BIOPHARMA, INC.

AI score

Very similar · 12 shared holders

Fairmount Funds Management LLC VR Adviser, LLC Logos Global Management LP

TSHA

Taysha Gene Therapies, Inc.

AI score

Very similar · 14 shared holders

Octagon Capital Advisors LP Polar Capital Holdings Plc MPM BioImpact LLC

QURE

uniQure N.V.

AI score

Very similar · 23 shared holders

JENNISON ASSOCIATES LLC MPM BioImpact LLC First Turn Management, LLC

RCUS

Arcus Biosciences, Inc.

AI score

Very similar · 20 shared holders

BAKER BROS. ADVISORS LP Logos Global Management LP Candriam S.C.A.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DNTH on your watchlist

Track score changes the day Dianthus Therapeutics, Inc. /DE/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DNTH a good stock to buy?

13F Pro's AI-powered analysis of Dianthus Therapeutics, Inc. /DE/ (DNTH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DNTH are available on the DNTH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DNTH is classified as a mid company.

Which hedge funds own DNTH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DNTH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Dianthus Therapeutics, Inc. /DE/'s investment landscape.